Japan’s Takeda Pharmaceutical (TYO: 4502) has announced the formal completion of its $62 billion acquisition of the rare disease specialist Shire.
Operating in around 80 countries or regions, the newly-formed entity will have global revenues of over $30 billion, and will focus on four main therapeutic areas - oncology, gastroenterology, neuroscience and rare diseases.
Chief executive Christophe Weber said he was “pleased to have completed the acquisition several months earlier than expected,” adding that the company seeks to deliver “highly-innovative medicines to patients around the world with expanded scale and geographical footprint.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze